Activated systemic inflammatory response at diagnosis reduces lymph node count in colonic carcinoma

Rory P Kennelly, Brenda Murphy, John O Larkin, Brian J Mehigan, Paul H McCormick

AIM: To investigate a link between lymph node yield and systemic inflammatory response in colon cancer.

METHODS: A prospectively maintained database was interrogated. All patients undergoing curative colonic resection were included. Neutrophil lymphocyte ratio (NLR) and albumin were used as markers of SIR. In keeping with previously studies, NLR ≥ 4, albumin < 35 was used as cut off points for SIR. Statistic analysis was performed using 2 sample t-test and χ² tests where appropriate.

RESULTS: Three hundred and two patients were included for analysis. One hundred and ninety-five patients had NLR < 4 and 107 had NLR ≥ 4. There was no difference in age or sex between groups. Patients with NLR of ≥ 4 had lower mean lymph node yields than patients with NLR < 4 [17.6 ± 7.1 vs 19.2 ± 7.9 (P = 0.036)]. More patients with an elevated NLR had node positive disease and an increased lymph node ratio (≥ 0.25, P = 0.044).

CONCLUSION: Prognosis in colon cancer is intimately linked to the patient’s immune response. Assuming standardised surgical technique and sub specialty pathology, lymph node count is reduced when systemic inflammatory response is activated.

Key words: Systemic inflammatory response; Lymph node yield; Lymph node count; Colon cancer; Colonic cancer; Neutrophil-lymphocyte ratio; Neutrophil to lymphocyte ratio; Lymph node ratio

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
INTRODUCTION

Prognosis in colon cancer is largely predicted by clinicopathological criteria, namely the TNM system which divides patients into groups based on tumour invasion, local nodal involvement and distant metastatic spread. Since its inception over 50 years ago[1], TNM has been used to predict patient prognosis following surgery. While easy to apply and reproducible, recent research has highlighted deficiencies in the TNM system. Higher absolute lymph node counts improve patient prognosis regardless of stage[2] and an increased lymph node ratio in node positive disease reduces prognosis[3,4], two variables not measured by TNM.

Tumour-host immunological response is an important factor in prognosis at both a local and systemic level[4,5], another feature not measured by TNM. Local response has been assessed by looking at lymphocytic infiltration of colonic tumour and an improved survival is seen in patients who have mounted a local lymphocytic response[6]. Readily available markers of systemic inflammatory response (SIR) have prognostic value in patients undergoing surgery for colon cancer[7]. A combination of C-reactive protein and albumin (the modified Glasgow prognostic score) and the neutrophil-lymphocyte ratio (NLR) have been proposed as surrogate markers of patient systemic immune response to cancer. A high modified Glasgow Prognostic Score (mGPS) and/or an elevated NLR (≥ 4) infer a poorer prognosis. A combination of an activated local response and the lack of an activated SIR imparts an improved prognosis[7], strengthening the link between cancer survival and immune response at both a local and systemic level.

To date, the information gleaned from lymph node harvest has revolved around absolute number and the presence or absence of cancer spread. Improved prognosis from higher lymph node counts has been explained as essentially a sampling error in patients with sub optimal surgical resection[8]. This explanation cannot account for the wide variance in yields experienced even in centres where radical excisions are performed as a matter of routine[9].

Lymph nodes are the first line of defence in the loco-regional immune response to cancer. It is possible that an increased local response to cancer results in lymph node hypertrophy resulting in an increased lymph node yield. Failure of a local response may result in less lymph node activation and allow for systemic “escape” resulting in activation of the systemic immune response. If this is the case, assuming standardised surgical and pathology techniques, a lower lymph node yield could be expected in patients with signs of an activated SIR in the preoperative period.

The aim of this study was to investigate a link between lymph node yields and systemic inflammatory response in patients undergoing surgery for colonic carcinoma.

MATERIALS AND METHODS

Patients who had undergone elective surgery for colon cancer between January 2007 and July 2013 were identified from a prospectively maintained database. Due to the known effect of radiotherapy on lymph node counts[10], rectal cancer patients were excluded. All surgeries were performed by the same subspecialty trained consultant surgeons and all samples analyzed by the same pathology department. Laparoscopic and open procedures were included.

Using a hospital-wide electronic patient record computer system, the results of pre-operative bloods drawn either on the day prior to or morning of surgery were recorded.

Neutrophil-lymphocyte ratio was derived from a standard white cell differential and in keeping with previous studies, an NLR of ≥ 4 and albumin < 35 were used as cut off levels indicating an activated SIR.

Statistical analysis was performed using Minitab v16 (Minitab Ltd. Coventry, United Kingdom). Continuous and categorical variables were analysed with 2 sample student’s t-test and χ2 tests where appropriate. Statistical analysis was performed by author RPK who has training in statistical methodology.

RESULTS

Three hundred and sixteen patients were identified for inclusion in the study. Fourteen patients were excluded due to incomplete data and analysis of CRP was ultimately abandoned as it was not routinely measured pre-operatively. The majority of the patients were male (168 vs 124) and the median age was 71. One hundred and seventy-eight patients had a laparoscopic

Core tip: A fascinating field of research is the relationship between systemic inflammatory response and loco-regional inflammatory response in colorectal cancer. This manuscript examines this relationship in a large cohort of patients from a tertiary referral centre. We measured systemic response by assessing serum markers at diagnosis and we measured local response by looking at pathological lymph node counts in the post operative surgical specimen. This is the first report to show that patients with evidence of an activated systemic inflammatory response at diagnosis have a reduced nodal harvest at time of surgery. This finding sheds light on the complex interaction between cancer and the patient.

This host-tumour response forms the basis for the most advanced cancer research today.
or lap-assisted operation. One hundred and twenty-four patients had a either a planned open operation or a lap to open conversion. Most patients were either stage II (45%) or stage III (37%) (Table 1). Lymph node count did not vary significantly based on operative approach, age or gender (Table 2).

Of the 302 patients included for analysis. One hundred and ninety-five patients had NLR < 4 and 107 had NLR ≥ 4. Patients with an NLR ≥ 4, (i.e., activated systemic inflammatory response) had a reduced total nodal count (17.6) compared to patients with an NLR of < 4 (19.2). Hypoalbuminaemia did not impact on lymph node count. Patients with low albumin and an elevated NLR were not more likely to have a reduced lymph node count than patients with elevated NLR alone (Table 3). NLR ≥ 4 correlated with a reduced lymph node yield (17 ± 7.1 vs 19.2 ± 7.9). A higher proportion of patients with NLR ≥ 4 had lymph node positive disease (Table 4).

**DISCUSSION**

The host-tumour response is at the forefront of cancer research and exploration of the relationship between the patient and their cancer has yielded success in areas previously resistant to traditional chemotherapy\(^{(11)}\). Higher lymph node counts correspond with improved prognosis in colon cancer\(^{(12)}\). The relationship is preserved within cancer stages\(^{(13)}\). An activated systemic inflammatory response, in the preoperative period, correlates with poor prognosis in colon cancer\(^{(12)}\). While the reason for this finding is not clearly defined it is possible that an activated SIR represents a loss of local control and is an early marker of systemic awareness of a heretofore localised cancer process. The data presented here propose a unifying explanation for these separately defined phenomena.

Previous work has shown that neutrophil lymphocyte ratios can predict survival in many cancer types\(^{(13)}\). Different ratios have been tested to find a reliable measure of activated systemic inflammatory response\(^{(14,15,16,17)}\). The ratio that carries the greatest level of evidence is NLR ≥ 4\(^{(16,17)}\). In our patient cohort, a preoperative elevated NLR correlated with a reduced lymph node yield (19 vs 17).

The clinical significance of a two-node difference may be questioned. While the finding is statistically significant it is worth asking whether there is any useful information to be gained. Cserni et al\(^{(18)}\) examined a large cohort of colon patients in the SEER database looking at the impact of nodal yield on survival. An improvement in prognosis was observed with increasing lymph node harvest. This finding was maintained in node negative and node positive patients. Indeed it was shown that with each additional node resected there is an associated increase in survival. Given this information, the findings in the current study may well provide important prognostic information.

Many studies have examined lymph node number and oncological outcome\(^{(19)}\). Lymph node counts below 12 correlate with poor outcome, a finding largely explained by variances in surgical quality\(^{(20)}\). However, even in good surgical specimens, low yields are sometimes encountered and many centres have questioned the validity of a binary marker of surgical quality in colon cancer\(^{(21,22)}\). Regardless of this on-going controversy,
in all hospitals.

The primary focus of our study is on the peri-

operative period but there is much scope for further

research in this field. We have not reported long term

outcomes and survival data in our patient cohort as the

median follow-up time period in the study group was

not of sufficient length. These patients will be followed

prospectively and outcome will be reported in future

planned analyses.

This study, albeit preliminary, may yield important

prognostic value for our patients. Pre-operative iden-
tification of SIR could potentially alter treatment deci-
sions, i.e., serve as an indication for adjuvant chemo-
therapy, determine frequency of clinical and radiological

surveillance as well as confer additional prognostic

information.

Although the mechanism remains poorly understood,
it is evident that there is an intrinsic link between the
host immune response and patient outcome in colon

cancer. The results of this study indicate that lymph

node count is reduced where systemic inflammatory

response is activated in colon cancer. We propose that

neutrophil-lymphocyte ratio can therefore be used to
predict nodal yield and provide additional valuable

information regarding prognosis.

**COMMENTS**

**Background**

A host systemic inflammatory response to a tumour has been shown to

negatively affect prognosis in patients undergoing surgery for colon

carcinoma. Surrogate markers of systemic inflammatory response researched
to date have included routine laboratory investigations such as serum
albumin, C-reactive protein and the neutrophil-lymphocyte ratio which together

comprise the modified glasgow prognostic score. A more pronounced systemic

inflammatory response as shown by a high glasgow prognostic score infers a

poor prognosis in colon cancer. Lymph node count in colon cancer has long

been established as a surgical quality indicator. Research has shown that a

higher lymph node yield confers improved prognosis, a phenomenon which

appears to be independent of nodal disease burden. This has previously been
attributed to selection bias with lower nodal yield thought to be associated with

the quality of the operating surgeon and examining histopathologist. However,
this does not explain the large variation in nodal yields that sub-specialist
centres encounter, where departments of highly specialised surgeons and

histopathologists are routinely involved in multi-disciplinary cancer care.

**Research frontiers**

The host-tumour immune response is a fascinating field of cancer research

| Table 5 Description of modified glasgow prognostic score |
|---------------------------------|
| mGPS | Score |
| Crp < 10, albumin ≥ 35 | 0 |
| Crp < 10, albumin < 35 | 0 |
| Crp > 10 | 1 |
| Crp > 10 and albumin < 35 | 2 |

mGPS: Modified glasgow prognostic score.

the lymph node count in both categories in the present
study was well above 12 therefore surgical quality is not
in question.

Other factors can impact on lymph node yield. Age,
gender and laparoscopic surgery can affect lymph node

count however these factors were not found to influence

yields in the present study. Lymph node counts are

highly dependent on quality of pathological examination

and this may represent the single greatest factor that

influences inter-institutional variability in nodal yields.[23]

A single sub-specialty pathology department analysed

all specimens in the present study limiting the impact of

the pathologist on lymph node harvest.

NLR ≥ 4 was compared to established measures of

patient prognosis. Positive to negative lymph node

ratios are a strong prognostic indicator in colonic car-
cinoma[31]. Prognosis falls as ratios increase and a
cut off of 0.25 (1 in 4 nodes positive) has particular

prognostic significance[24]. In the current patient cohort,
a significant link is apparent between NLR and LNR of

0.25 and above. Lymph node ratios are dependent

on absolute lymph node count and it is possible that

previous findings regarding lymph node ratios are in

fact a surrogate for the relationship between local and

systemic inflammatory responses to cancer.

How systemic inflammatory response and cancer

interact is a matter of debate. One theory suggests

suppression of anti-tumour immunity by recruiting regu-
latory T cells and activating chemokines[25] resulting in
tumour growth and spread. It has been proposed that

SIR acts as a marker of pre-existing comorbid disease and

high risk pathological tumour characteristics (i.e.,
lymphovascular invasion, peritoneal involvement.) Inter-
estingly, studies designed to explore this question have

d not shown a link[26].

A significant relationship was not shown for albumin

and lymph node yield in our study. This was not an

unexpected finding given previous work by the Glasgow
group. The original Glasgow Prognostic Score assigned a

score of 1 for hypoalbuminaemia. Further work showed

no prognostic significance for hypoalbuminaemia alone[30]

(Table 5). The modified score only attributes a score for a

low albumin if there is a concomitant elevated C reactive

protein. As CRP was not measured in the present study,

albumin levels did not provide any added benefit.

Our study has limitations. Due to the nature of the

institutional database, patient information is not ava-

ilable regarding co-morbid conditions. However, all

included patients represent elective surgical candidates,
deemed fit for surgery with no acute illness precluding

an operation. The exclusion of emergency procedures

lends some security regarding confounding causes of
evolved markers of systemic inflammatory response.

We were unable to complete our analysis of CRP due
to levels not being available on the majority of our

patients. While a pre-operative CRP is desirable, it
does not form part of the standard pre-operative work

up for our patients and is unlikely to be a routine test

performed in most institutions. All patients undergo a

full blood count prior to surgery therefore neutrophil

lymphocyte ratio should be a readily available measure

in all hospitals.

Although the mechanism remains poorly understood,

it is evident that there is an intrinsic link between the

host immune response and patient outcome in colon

cancer. The results of this study indicate that lymph

node count is reduced where systemic inflammatory

response is activated in colon cancer. We propose that

neutrophil-lymphocyte ratio can therefore be used to

predict nodal yield and provide additional valuable

information regarding prognosis.

**REFERENCES**

[1] Kennelly RP et al. SIR and lymph node count. WJGO 2016;8(8):626.

[2] WJGO | www.wjgnet.com | August 15, 2016 | Volume 8 | Issue 8 |
that promises success in offering new treatment modalities in areas previously resistant to more conventional therapies. Current research supports that neutrophil lymphocyte ratio and similar markers of systemic inflammatory response can predict survival in many cancer types, likewise with local inflammatory response as characterised by tumour-infiltrating lymphocytes. These phenomena are at present not incorporated into any staging or classification system for colon cancer, despite the overwhelming evidence that they provide invaluable prognostic information. Considering this wealth of information, current research is exploring the exciting realm of immunotherapy, for which many clinical trials are underway.

Innovations and breakthroughs

The relationship of prognosis in colon cancer with systemic inflammatory response has been researched to date, as has with lymph node yield. To the authors’ knowledge however, this is the first study to examine a link between these two phenomena. The study supports that poor prognosis in colon cancer is due in part to failed or impeded local immune response to a tumour and subsequent systemic loss of control. The findings may also explain why lymph node counts are often highly variable, even in sub-specialty tertiary referral centres where variance in surgical and histopathological quality is unlikely to be a major confounding factor. This research suggests that the current focus on an absolute number of nodes as an indicator of quality is perhaps flawed, and a change in perspective with regards to lower-than-expected nodal yields should be employed.

Applications

The results of this study may offer important prognostic value for the patients. In identifying SIR pre-operatively, the authors can identify patients in whom lower nodal yield and a poorer prognosis is anticipated. This may potentially alter post-operative course of treatment, i.e., serve as an indication for adjuvant chemotherapy, determine frequency of clinical and radiological surveillance, as well as pave the way for the development of novel pre-operative immunotherapeutic interventions.

Terminology

Systemic inflammatory response (SIR): Reaction to an infectious or non-infectious stimulant by activation of whole body inflammatory cascade following failure of local immunological homeostasis; lymph node yield: Number of lymph nodes identified in pathological specimen following oncological resection; neutrophil-lymphocyte ratio (NLR): Ratio of circulating neutrophils to lymphocytes. A circulating neutrophilia relative to a lymphopenia is a surrogate marker of systemic inflammatory response. In keeping with previous studies, we chose a NLR of ≥ 4:1 as the cut-off for SIR; lymph node ratio: Ratio of positive to negative nodes in a specimen.

Peer-review

The manuscript describes findings of statistical-analysis to assess a link between lymph node yields and systemic inflammatory response in patients undergoing for colon carcinoma. Authors suggest an intrinsic link between the host immune-response and patient outcome in colon cancer, and propose that neutrophil-lymphocyte ratio can be used to predict nodal yield and provide additional valuable information regarding prognosis. This article is concisely written, and contains interesting findings.

REFERENCES

1. Denois P, Schwartz D. General rules for classification of cancers and presentation of the therapeutic results. Mémoires. Académie de chirurgie (France) 1959; 85: 15-16
2. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21: 2912-2919 [PMID: 12885809 DOI: 10.1200/JCO.2003.05.062]
3. Chen SL, Steele SR, Elberhardt J, Zhu K, Bitchik A, Stojadinovic A. Lymph node ratio as a quality and prognostic indicator in stage III colon cancer. Ann Surg 2011; 253: 82-87 [PMID: 21135690 DOI: 10.1097/SLA.0b013e3181ff7a80]
4. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545 [PMID: 11229684 DOI: 10.1016/S0140-6736(00)03606-0]
5. Bremner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014; 383: 1490-1502 [PMID: 24225001 DOI: 10.1016/S0140-6736(13)61469-9]
6. Klintup K, Mäkinen JM, Kauppila S, Väre PO, Melkko J, Tuominen H, Tuppurainen K, Mäkelä J, Karttunen TJ, Mäkinen MJ. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005; 41: 2654-2655 [PMID: 16239109 DOI: 10.1016/j.ejca.2005.07.017]
7. Roxburgh CS, Salmon JD, Horgan PG, Oien KA, McMillan DC. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 2009; 249: 788-793 [PMID: 19387324 DOI: 10.1097/SLA.0b013e181a36738]
8. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007; 99: 433-441 [PMID: 17374833 DOI: 10.1093/jnci/djk092]
9. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colorectal cancer: complete mesocolic excision and central ligation--technical notes and outcome. Colorectal Dis 2009; 11: 354-364; discussion 364-365 [PMID: 19016817 DOI: 10.1111/j.1463-1318.2008.01735.x]
10. Persiani R, Biondi A, Gambartaca MA, Bertucci Zoccoli M, Vecchio FM, Tufo A, Coco C, Valentini V, Doglietto GB, D’Ugo D. Prognostic implications of the lymph node count after neoadjuvant treatment for rectal cancer. Br J Surg 2014; 101: 133-142 [PMID: 24375303 DOI: 10.1002/bjs.9341]
11. Fliherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippio JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819 [PMID: 20818844 DOI: 10.1056/NEJMoa1002011]
12. Roxburgh CS, Wallace AM, Guthrie GK, Horgan PG, McMillan DC. Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative surgery for colon cancer. Colorectal Dis 2010; 12: 987-994 [DOI: 10.9738/INTSURG-D.13-00118.1]
13. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS, Foulis AK, Horgan PG, McMillan DC. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcomes Study in Cancer 2011; 47: 2633-2641 [PMID: 21724383 DOI: 10.1016/j.ejca.2011.03.028]
14. Chiang SF, Hung HY, Tang R, Chanchien CR, Chen JS, You YT, Chang JM, Lin JC. Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively? Int J Colorectal Dis 2012; 27: 1347-1357 [PMID: 22466305 DOI: 10.1007/s00384-012-1459-x]
15. Mallappa S, Sinha A, Gupta S, Chadwick SJ. Preoperative neutrophil to lymphocyte ratio ≥ 5 is a prognostic factor for recurrent colorectal cancer. Colorectal Dis 2013; 15: 323-328 [PMID: 22958479 DOI: 10.1111/codi.12008]
16. Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, Weissmuller M, Schaberl-Moser R, Samonigg H, Stojadinovic T, Gerger A. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 2013; 109: 395-400 [PMID: 23820252 DOI: 10.1038/bjc.2013.346]
17. Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, Wan DS, Pan ZZ. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage II A colon cancer. Int J Colorectal Dis 2010; 25: 1427-1433 [PMID: 20821217 DOI: 10.1007/s00384-010-1052-0]
18. Cserni G, Vinh-Hung V, Burzykowski T. Is there a minimum number of lymph nodes that should be histologically assessed for a reliable nodal staging of T3N0M0 colorectal carcinomas? J Surg Oncol 2012; 105: 155-160 [PMID: 22061665 DOI: 10.1002/jso.22603]
19 Johnson PM, Porter GA, Ricciardi R, Baxter NN. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIIB and IIIC colon cancer. J Clin Oncol 2006; 24: 3570-3575 [PMID: 16877723 DOI: 10.3333/jco.2013.29.3.89]

20 Lykke J, Roikjaer O, Jess P. The relation between lymph node status and survival in Stage I-III colon cancer: results from a prospective nationwide cohort study. Colorectal Dis 2013; 15: 559-565 [PMID: 23061638 DOI: 10.1111/codi.12059]

21 Mathis KL, Green EM, Sargent DJ, Delaney C, Simmang CL, Nelson H. Surgical quality surrogates do not predict colon cancer survival in the setting of technical credentialing: a report from the prospective COST trial. Ann Surg 2013; 257: 102-107 [PMID: 23059506 DOI: 10.1097/SLA.0b013e318260a8e6]

22 Li DG, Di C, Scilletta R, Scilletta B, Paleo S. Colorectal cancer and lymph nodes: the obsession with the number 12. World J Gastroenterol 2014; 20: 1951-1960 [PMID: 24587671 DOI: 10.3748/wjg.v20.i8.1951]

23 Chapman B, Paquette C, Tooko C, Schwartz M, Osler T, Weaver D, Wilcox R, Hyman N. Impact of Schwartz enhanced visualization solution on staging colorectal cancer and clinicopathological features associated with lymph node count. Dis Colon Rectum 2013; 56: 1028-1035 [PMID: 23929011 DOI: 10.1097/DCR.0b013e31829041ha]

24 Vaccaro CA, Im V, Rossi GL, Quintana GO, Benati ML, Perez de Arenaza D, Bonadeo FA. Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons. Dis Colon Rectum 2009; 52: 1244-1250 [PMID: 19571700 DOI: 10.1007/DCR.0b013e31829c41ba]

25 Kantola T, Klintrup K, Väyrynen JP, Vomanen J, Bloigu R, Karhu T, Herzig KH, Näplänkangas J, Mäkelä J, Karttunen TJ, Tuomisto A, Mäkinen MJ. Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer 2012; 107: 1729-1736 [PMID: 23059742 DOI: 10.1038/bjc.2012.456]

26 McMillan DC, Crozier JE, Canna K, Angerson WJ, Mcardle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 2007; 22: 881-886 [PMID: 17245566 DOI: 10.1007/s00384-006-0259-6]
